Nyxoah Shares Surge On Strong Q4 Preliminary Revenue

Nyxoah expects Q4 2025 net revenue to rise approximately 348% to €5.7m (≈€3.5m after deducting deferred revenue) and full-year net revenue to be about €10.0m, up ~122% year-over-year; however, after excluding deferred revenue the company indicates full-year net revenue will be roughly €3.7m lower than the prior year. The company reported ~€47.9m in cash, cash equivalents and financial assets as of Dec. 31, 2025, expects Q1 2026 revenue to increase ~25% versus Q4, and is scaling its U.S. Genio launch (FDA-approved Aug 2025) with 145 surgeons trained and 57 U.S. accounts activated.

Analysis

Market structure: Nyxoah (NYXH) is the direct beneficiary of the FDA-approved Genio rollout — headline Q4 revenue +348% to €5.7M (net after deferred ~€3.5M) and 57 U.S. activated accounts signal a classic small-base, high-growth setup where early share gains vs. incumbents (e.g., Inspire/CPAP makers) are possible but local. Pricing power is limited today (installation-driven revenue) and meaningful margin expansion requires scale (hundreds of accounts), so near-term winners are device suppliers, trained surgeons and select hospital systems; large-cap CPAP players see minimal immediate pressure.

Risk assessment: Key tail risks are post-market safety events, unfavorable reimbursement coding/coverage, and a slower surgical adoption curve; a recall or negative safety signal could erase equity value quickly. Time horizons: immediate (days) — JPM presentation (Jan 15) and knee-jerk volatility; short-term (weeks–months) — Q1 revenue cadence and account activations; long-term (12–36 months) — durable share capture and payer acceptance. Hidden dependencies include OR scheduling capacity, surgeon training throughput (145 trained), and device supply constraints.

Trade implications: Tactical trade: asymmetric long exposure to NYXH ahead of JPM and Q1 cadence with strict risk controls; larger conviction requires proof points (quarterly sequential revenue growth >25% and activated accounts >120 by Mar 31, 2026). Options/hedge: use 9–12 month LEAP calls to cap downside or pair long NYXH vs short equal-$ IHI (iShares U.S. Medical Devices ETF) to isolate idiosyncratic upside. Cross-asset: negligible macro impact, but expect elevated options IV and potential small-cap healthcare alpha dispersion.

Contrarian angle: The market is focused on headline % growth but under-appreciates deferred-revenue distortion — underlying recurring revenue may be flat or down YoY per company note. If NYXH cannot convert trained surgeons into weekly implants (threshold: >4 implants/account/month), downside is material. Historical parallel: hypoglossal stimulator adoption (Inspire) took multiple years; overpaying for early rollout metrics is a common pitfall.

Key Decisions for Investors

• Establish a 2–3% long position in NYXH (ticker: NYXH) ahead of the Jan 15 J.P. Morgan presentation; set a hard stop-loss at -20% and take-profit scale at +40% and +60% (sell 50% at +40%, rest at +60%) within a 9–12 month horizon, contingent on sequential revenue and account activation metrics.
• If risk-tolerant, buy 12-month NYXH LEAP calls (expiry Jan 2027) equal to ~1% notional as a leveraged play; size to lose no more than 1–1.5% of portfolio if IV collapses. Close if Q1 revenue growth vs Q4 <15% or activated U.S. accounts <90 by Mar 31, 2026.
• Implement a hedged pair: long NYXH (1%) and short IHI (iShares U.S. Medical Devices ETF) equal dollar (1%) to isolate company-specific upside; rebalance monthly and unwind if NYXH underperforms IHI by >30% in 60 days.
• Avoid outright short of NYXH unless clear adverse events or reimbursement denial occur; prepare a catalyst-based short: initiate if cash falls below €25M or company misses sequential revenue guidance by >20% in any quarter (timeframe 3–6 months).